Depression
Conditions
Keywords
Major Depression, Major Depressive Disorder, Persistent Depressive Disorder, Cognitive Behavioral Therapy, Biomarkers
Brief summary
The purpose of this study is to locate clinical markers (for example, interviews, questionnaires, and computer tasks) and biological markers (for example, physiological, blood-based, or electroencephalography measurements) that predict response to cognitive behavioral therapy for depression.
Detailed description
Forty adult outpatients with major depressive disorder or persistent depressive disorder will receive up to 20 sessions of cognitive behavioral therapy for depression over 16 weeks. Participants will complete clinical measures (interviews, questionnaires, and computer-based tasks) and biological measures (blood tests, physiological measurements, electroencephalography ) before, during, and after treatment.
Interventions
BEHAVIORALCognitive Behavioral Therapy
Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
Sponsors
University Health Network, Toronto
Dalhousie University
Centre for Addiction and Mental Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Major Depressive Disorder or Persistent Depressive Disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition * Must be fluent in English * Must be capable to give informed consent
Exclusion criteria
* Lifetime diagnosis of Schizophrenia, Schizoaffective Disorder, Bipolar Disorder * Current Alcohol or Drug Use Disorder (except tobacco or caffeine) * Current psychotic symptoms * Acute suicide risk * Psychological treatment for depression initiated during the past three months * Pharmacological treatment for depression initiated/changed during the past three months * Previous non-response to two or more adequate trials of pharmacotherapy * Current significant neurological disorder, head trauma, or unstable medical conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 16 weeks | Depression symptom severity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quick Inventory of Depressive Symptomatology (QIDS) | 16 weeks | Depression symptom severity |
| World Health Organization Quality of Life Short Version (WHOQOL-BREF) | 16 weeks | Quality of life |
| Hamilton Depression Rating Scale (Ham-D) | 16 weeks | Depression symptom severity |
| Beck Depression Inventory (BDI) | 16 weeks | Depression symptom severity |
| Work and Social Adjustment Scale (WSAS) | 16 weeks | Functioning and impairment |
Countries
Canada
Outcome results
None listed